Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.
Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, Tsunoda AT, Cantú-de-León DF, Ramondetta LM, Manchana T, Crotzer DR, McNally OM, Riege M, Scambia G, Carvajal JM, Di Guilmi J, Rendon GJ, Ramalingam P, Fellman BM, Coleman RL, Frumovitz M, Ramirez PT. Schmeler KM, et al. Among authors: mcnally om. Int J Gynecol Cancer. 2021 Oct;31(10):1317-1325. doi: 10.1136/ijgc-2021-002921. Epub 2021 Sep 7. Int J Gynecol Cancer. 2021. PMID: 34493587
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S, Steer C, DeFazio A, Quinn M, Obermair A, Friedlander M, Francis J, O'Brien S, Goss G, Wyld D, Australian Ovarian Cancer Study Group, Webb P; Ovarian Cancer Patterns of Care Study Group. Jordan S, et al. Gynecol Oncol. 2013 May;129(2):310-7. doi: 10.1016/j.ygyno.2013.02.007. Epub 2013 Feb 9. Gynecol Oncol. 2013. PMID: 23403164 Free article.
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer.
Moloney K, Janda M, Frumovitz M, Leitao M, Abu-Rustum NR, Rossi E, Nicklin JL, Plante M, Lecuru FR, Buda A, Mariani A, Leung Y, Ferguson SE, Pareja R, Kimmig R, Tong PSY, McNally O, Chetty N, Liu K, Jaaback K, Lau J, Ng SYJ, Falconer H, Persson J, Land R, Martinelli F, Garrett A, Altman A, Pendlebury A, Cibula D, Altamirano R, Brennan D, Ind TE, De Kroon C, Tse KY, Hanna G, Obermair A. Moloney K, et al. Int J Gynecol Cancer. 2021 May;31(5):647-655. doi: 10.1136/ijgc-2020-002315. Epub 2021 Mar 4. Int J Gynecol Cancer. 2021. PMID: 33664126 Free PMC article.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Cohen PA, et al. Int J Gynecol Cancer. 2022 Apr 4;32(4):560-565. doi: 10.1136/ijgc-2021-002999. Int J Gynecol Cancer. 2022. PMID: 34551895 Clinical Trial.
VIN 3: a clinicopathologic review.
McNally OM, Mulvany NJ, Pagano R, Quinn MA, Rome RM. McNally OM, et al. Int J Gynecol Cancer. 2002 Sep-Oct;12(5):490-5. doi: 10.1046/j.1525-1438.2002.01140.x. Int J Gynecol Cancer. 2002. PMID: 12366668
82 results